ArticleBMC medical imaging2026
CT imaging characteristics of ovarian small cell carcinoma: correlation with clinicopathology and prognosis.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSmall cell carcinoma of the ovary (SCCO) is a rare, highly aggressive malignancy comprising pulmonary type (SCCOPT) and hypercalcemic type (SCCOHT). Clinical presentations are nonspecific, and CT features remain poorly defined. We aimed to characterize CT findings of SCCO, compare subtypes, and evaluate associations with pathology and outcomes.
methodsWe retrospectively analyzed 42 patients with pathologically confirmed SCCO (8 institutional cases and 34 literature-derived cases). Clinical, pathological, and follow-up data were collected. Pre-treatment contrast-enhanced CT images were independently reviewed by two senior radiologists. Imaging features were correlated with immunohistochemical markers and survival outcomes.
resultsThe cohort included 22 SCCOPT and 20 SCCOHT cases. Compared with SCCOPT, SCCOHT patients were younger (25.5 vs. 54.0 years, P < 0.0001), had larger tumors (15.0 vs. 11.1 cm, p = 0.039), and more frequently had hypercalcemia (55.0% vs. 0%, p = 0.0002). On CT, SCCOPT commonly presented as irregular (63.6%), ill-defined (59.1%) solid or mixed masses with moderate-to-marked enhancement and frequent metastases, whereas SCCOHT typically appeared as large unilateral, well-circumscribed cystic–solid tumors with mild-to-moderate peripheral enhancement and central necrosis, often mimicking benign lesions. BRG1 loss was associated with lower enhancement and reduced invasiveness (r = − 0.64 to − 0.41, p < 0.05), while high Ki-67 expression correlated with irregular morphology, marked enhancement, and metastasis (r = 0.33–0.47, p < 0.05). In SCCOPT, lower chromogranin A expression correlated with ill-defined margins (r = − 0.45, p = 0.035). Median overall survival remained poor (14.4 months for SCCOPT vs. 11.0 months for SCCOHT). In multivariable Cox analysis, irregular morphology (HR = 3.75, p = 0.03) and bowel invasion (HR = 3.13, p = 0.03) independently predicted worse overall survival.
conclusionCT features differ between SCCOPT and SCCOHT and show meaningful associations with immunohistochemical markers and outcomes. Integrating imaging with molecular pathology may aid preoperative risk stratification and prognostic assessment in this rare malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.